Neurocrine Biosciences, Inc.
NBIX
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.32B
Close$
$382.71
179.5% upside
Current Fair Value
179.5% upsideUndervalued by 179.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.32 Billion |
|---|---|
| Enterprise Value | $14.72 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $4.81 |
| Beta | 0.4 |
| Outstanding Shares | 101,000,000 |
Return
| Return on Equity | 17.68% |
|---|---|
| Return on Assets | 13.16% |
| Return on Invested Capital | 17.56% |
Valuation & Multiples
| P/E Ratio | 20.2 |
|---|---|
| PEG | 58.86 |
| Price to Sales | 4.15 |
| Price to Book Ratio | 3.51 |
| Enterprise Value to Revenue | 4.36 |
| Enterprise Value to EBIT | 18.7 |
| Enterprise Value to Net Income | 20 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$1.85
Average shareholder expectationRevenue Estimate
$890.33 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$1.91
Average shareholder expectationRevenue Estimate
$1.04 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 103.23% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.36%▼ 101.14% |
|---|---|
| Total Invested | $51.13M▼ 99.70% |
| Investors Holding | 26▼ 771.00% |
ESG Score
No data
About Neurocrine Biosciences, Inc.
2,000 employees
CEO: Kevin Gorman Neurocrine Biosciences, Inc. is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies for a range of neurological, endocrine, and psychiatric conditions. Its established portfol...